Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, Caroline, Thomas, Luc, Bondarenko, Igor, O'Day, Steven, Weber, Jeffrey, Garbe, Claus, Lebbe, Celeste, Baurain, Jean-François, Testori, Alessandro, Grob, Jean-Jacques, Davidson, Neville, Richards, Jon, Maio, Michele, Hauschild, Axel, Miller, Wilson H., Gascon, Pere, Lotem, Michal, Harmankaya, Kaan, Ibrahim, Ramy, Francis, Stephen, Chen, Tai-Tsang, Humphrey, Rachel, Hoos, Axel, Wolchok, Jedd D.·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1104621

Cited by (1,022)

Items 601–700 of 1,022

  1. Immune checkpoint blockade therapy
    Thomas Wieder, Thomas Eigentler, Ellen Brenner, Martin Röcken · 2018 · Journal of Allergy and Clinical Immunology
  2. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
    Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen et al. · 2019 · Translational Oncology
  3. Evidence and impact of neutrophil extracellular traps in malignant melanoma
    Fiona Schedel, Sarah Mayer‐Hain, Karin Pappelbaum, Dieter Metze, Martin Stock, Tobias Goerge, Karin Loser, Cord H. Sunderkötter, Thomas Anton Luger, Carsten Weishaupt · 2019 · Pigment Cell & Melanoma Research
  4. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
    Giulia Di Dalmazi, Silvia Ippolito, Isabella Lupi, Patrizio Caturegli · 2019 · Expert Review of Endocrinology & Metabolism
  5. Erratum: Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
    Dalil Hannani, Marie Vétizou, David Pierre Enot, Sylvie Rusakiewicz, Nathalie Chaput, David Klatzmann, Mélanie Desbois, Nicolas Jacquelot, Nadège Vimond, Salem Chouaı̈b et al. · 2015 · Cell Research
  6. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
    Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski · 2015 · BioMed Research International
  7. CTLA ‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
    Luis H. Camacho · 2015 · Cancer Medicine
  8. Experimental mouse tumour models: what can be learnt about human cancer immunology?
    Glenn Dranoff · 2011 · Nature reviews. Immunology
  9. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy
    Kui Li, Hongqi Tian · 2018 · Journal of drug targeting
  10. Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy
    ‪Yasmin Maor‬‏, Stephen D. H. Malnick · 2013 · International Journal of Hepatology
  11. Neurological immune-related adverse events of ipilimumab
    Ilja Bot, Christian U. Blank, Willem J. Boogerd, Dieta Brandsma · 2013 · Practical Neurology
  12. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
    Jan Bogaerts, Matthew Robert Sydes, Nicola Keat, Andrea McConnell, Al B. Benson, Alan Loh Ho, Arnaud D. Roth, Catherine Fortpied, Cathy Eng, Clare Peckitt et al. · 2014 · European Journal of Cancer
  13. Cutaneous melanoma
    Alpaslan Tasdogan, Ryan Joseph Sullivan, Alexander Katalinic, Célèste Lebbé, Dagmar Whitaker, Susana Puig, Lonneke Veronique van de Poll-Franse, Daniela Massi, Dirk Schadendorf · 2025 · Nature Reviews Disease Primers
  14. Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication
    Seongseok Yun, Nicole D. Vincelette, Iyad S. M. Mansour, Dana J. Hariri, Sara Motamed · 2015 · Case Reports in Oncological Medicine
  15. Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
    Corine Bertolotto · 2013 · Scientifica
  16. Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
    Shigehisa Kitano, Michael Andrew Postow, Carly G.K. Ziegler, Deborah Kuk, Katherine S. Panageas, Czrina A. Cortez, Teresa S. Rasalan, Matthew J. Adamow, Jianda D. Yuan, Phillip Wong et al. · 2014 · Cancer Immunology Research
  17. Mucosal Melanoma: Epidemiology, Biology and Treatment
    Kristen Renee Spencer, Janice M. Mehnert · 2015 · Cancer treatment and research
  18. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Samantha Elizabeth Bowyer, Prashanth Prithviraj, Paul C. Lorigan, James Larkin, Grant A. McArthur, Victoria G. Atkinson, Michael Millward, Muoi Khou, Stefan Diem, Sangeetha Ramanujam et al. · 2016 · British Journal of Cancer
  19. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
    Antoine Millet, Anthony R. Martin, Cyril Ronco, Stéphane Rocchi, Rachid Benhida · 2016 · Medicinal Research Reviews
  20. Orchestrating immune check-point blockade for cancer immunotherapy in combinations
    José Luis Perez‐Gracia, Sara Labiano, Maria Esperanza Rodriguez-Ruiz, Miguel F. Sanmamed, Ignacio Melero · 2014 · Current Opinion in Immunology
  21. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
    Kevin Joseph Harrington, Igor J. Puzanov, Joel Randolph Hecht, Frank Stephen Hodi, Zsolt Roland Szabó, Swami Murugappan, Howard L. Kaufman · 2015 · Expert Review of Anticancer Therapy
  22. Targeting myeloid cells in the tumor sustaining microenvironment
    Jonathan Schupp, Franziska K. Krebs, Niklas Zimmer, Emily R. Trzeciak, Detlef Schuppan, Andrea Tuettenberg · 2017 · Cellular Immunology
  23. Increasing cure rates of solid tumors by immune checkpoint inhibitors
    Weijie Ma, Ruobing Xue, Zheng Gang Zhu, Hizra Farrukh, Wenru Song, Tianhong Li, Lei Zheng, Chong-xian Pan · 2023 · Experimental Hematology and Oncology
  24. Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
    Wouter V. Vogel, Aurélie Guislain, Pia Kvistborg, Ton N. Schumacher, John B.A.G. Haanen, Christian U. Blank · 2011 · Journal of Clinical Oncology
  25. Melanoma as a model tumour for immuno-oncology
    Michele Maio · 2012 · Annals of Oncology
  26. Ipilimumab-induced acute severe colitis treated by infliximab
    Cécile Pagès, Jean Marc Gornet, Gentiane Monsel, Matthieu Allez, Philippe Bertheau, Martine Bagot, Célèste Lebbé, Manuelle A Viguier · 2013 · Melanoma Research
  27. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
    Xin Hong, Ryan Joseph Sullivan, Mark Kalinich, Tanya Todorova Kwan, Anita Giobbie‐Hurder, Shiwei Pan, Joseph A. LiCausi, John D. Milner, Linda T. Nieman, Ben S. Wittner et al. · 2018 · Proceedings of the National Academy of Sciences
  28. Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer
    Yinyin Yuan · 2014 · Journal of The Royal Society Interface
  29. Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
    Julien Péron, Denis Maillet, Hui Kong Gan, Eric Xueyu Chen, Benoît You · 2013 · Journal of Clinical Oncology
  30. Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
    Teresa M. Petrella, Richard G. Tozer, Karl Bélanger, Kerry J. J. Savage, Ralph Wong, Michael Smylie, Suzanne Kamel‐Reid, Victor A. Tron, Bingshu E. Chen, Naomi N. H. Hunder et al. · 2012 · Journal of Clinical Oncology
  31. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)
    Gil Redelman‐Sidi, Olivier Alain Michielin, Carlos Cervera, Camillo Ribi, José María Aguado, Mario Fernández‐Ruiz, Oriol Manuel · 2018 · Clinical Microbiology and Infection
  32. BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
    Alexander Marzuka-Alcalá, Keith T. Flaherty · 2012 · Clinical Cancer Research
  33. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
    Adi Nosrati, Katy K. Tsai, Simone M. Goldinger, Paul C. Tumeh, Barbara A. Grimes, Kimberly Leticia Loo, Alain Patrick Algazi, Thi Dan Linh Nguyen‐Kim, Mitchell P. Levesque, Reinhard Dummer et al. · 2017 · British Journal of Cancer
  34. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
    Charlotte Eielson Ariyan, Mary Sue Brady, Robert H. Siegelbaum, Jian Hu, Danielle M. Bello, Jamie Green Rand, Charles Fisher, Robert A. Lefkowitz, Kathleen S. Panageas, Melissa P. Pulitzer et al. · 2018 · Cancer Immunology Research
  35. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Nikolaus Benjamin Wagner, Andrea Forschner, Ulrike Leiter, Claus Garbe, Thomas Eigentler · 2018 · British Journal of Cancer
  36. Immunotherapy in advanced gastric cancer, is it the future?
    Clélia Coutzac, Simon Pernot, Nathalie Chaput, Aziz Zaanan · 2018 · Critical Reviews in Oncology/Hematology
  37. Clinical pharmacology considerations for the development of immune checkpoint inhibitors
    Sheng, Jennifer, Srivastava, Shivani, Sanghavi, Kinjal, Lu, Zheng, Schmidt, Brian J., Bello, Akintunde, Gupta, Manish · 2017 · The Journal of Clinical Pharmacology
  38. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    Omar Mohammed Abdel-Rahman, Mona Fouad · 2016 · Therapeutic Advances in Respiratory Disease
  39. T cell checkpoint regulators in the heart
    Nir Grabie, Andrew H. Lichtman, Robert F. Padera · 2019 · Cardiovascular Research
  40. Targeted therapy for melanoma: rational combinatorial approaches
    Lawrence N. Kwong, Michael A. Davies · 2013 · Oncogene
  41. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
    Lidia Yshii, Christina Gebauer, Béatrice Pignolet, Emilie Mauré, Clémence Queriault, Mandy Pierau, Hiromitsu Saito, 鈴木 昇, Monika Christine Brunner-Weinzierl, Jan Bauer et al. · 2016 · Brain
  42. The expanding role of immunotherapy
    Juan Martín-Liberal, María Ochoa de Olza, Cinta Hierro, Alena Gros, Jordi Ahnert Rodon, Josep M. Tabernero · 2017 · Cancer Treatment Reviews
  43. Combatting Mucosal Melanoma: Recent Advances and Future Perspectives
    Helen E.J. Tyrrell, Miranda Payne · 2018 · Melanoma Management
  44. T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
    Aude G. Chapuis, Ilana M. Roberts, John A. Thompson, Kim Allyson Margolin, Shailender Bhatia, Sylvia M. Lee, Heather L. Sloan, Ivy P. Lai, Erik A. Farrar, Felecia D. Wagener et al. · 2016 · Journal of Clinical Oncology
  45. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
    Nathan I. Cherny, Elisabeth G.E. de Vries, Urania G. Dafni, Elizabeth S. Garrett-Mayer, Shannon E. McKernin, Martine J Piccart, Nicola Jane Latino, Jean-Yves Douillard, Lowell E. Schnipper, Mark R. Somerfield et al. · 2019 · Journal of Clinical Oncology
  46. Immune checkpoint inhibitors win the 2018 Nobel Prize
    Pei‐Wei Huang, John Wen‐Cheng Chang · 2019 · Biomedical Journal
  47. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials
    Fang Yang, Svetomir N. Markovic, Julian R. Molina, Thorvardur Ragnar Halfdanarson, Lance C. Pagliaro, Ashish Vittalrao Chintakuntlawar, Rutian Li, Jia Wei, Lifeng Wang, Baorui Liu et al. · 2020 · JAMA Network Open
  48. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
    R. Kim, Minsuk Kwon, Minae An, S.T. Kim, Simon A. Smith, Arsène‐Bienvenu Loembé, Peter G. S. Mortimer, Joshua Armenia, Natalia Lukashchuk, Neelam Shah et al. · 2021 · Annals of Oncology
  49. Immune checkpoints in cancer clinical trials
    Elad Sharon, HOWARD Z. STREICHER, Priscila Hermont Goncalves, Helen X. Chen · 2014 · 癌症：英文版
  50. Recent advances in targeted nanoparticles drug delivery to melanoma
    Jun Li, Yujue Wang, Ruijing Liang, Xiangjie An, Ke Wang, Guanxin Shen, Yating Tu, Jintao Zhu, Juan Tao · 2014 · Nanomedicine Nanotechnology Biology and Medicine
  51. Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial
    Jeroen Elassaiss‐Schaap, Stefaan Rossenu, Andreas Lindauer, SP Kang, Rik de Greef, JR Sachs, DP de Alwis · 2016 · CPT Pharmacometrics & Systems Pharmacology
  52. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
    Shuncong Wang, Yewei Liu, Yuanbo Feng, Jian Zhang, Johannes V. Swinnen, Yue Li, Yicheng Ni · 2019 · Cancers
  53. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
    Paola Queirolo, Francesco Spagnolo, Paolo A. Ascierto, Ester Simeone, Paolo Marchetti, Alessandro Scoppola, Michele Del Vecchio, Lorenza Di Guardo, Michele Maio, Anna Maria Di Giacomo et al. · 2014 · Journal of Neuro-Oncology
  54. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers
    Georgia E. Ritchie, Harry Michael Gasper, Johnathan Man, Sarah J. Lord, Ian C. Marschner, Michael Leonard Friedlander, Chee Khoon Lee · 2018 · JAMA Oncology
  55. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1 -like status, tumor-infiltrating immune cells and survival
    Marcelo Sobral‐Leite, Koen K Van de Vijver, Magali Michaut, Rianne van der Linden, Gerrit K. J. Hooijer, Hugo M. Horlings, Tesa Severson, Anna Marie Mulligan, Nayana Weerasooriya, Joyce Sanders et al. · 2018 · OncoImmunology
  56. Microbiota in cancer development and treatment
    Muhammad Hassan Raza, Kamni Gul, Abida Arshad, Naveeda Riaz, Usman Waheed, Abdul Rauf, Fahad M. Aldakheel, Shatha Ahmed Alduraywish, Maqbool Ur Rehman, Muhammad Abdullah et al. · 2018 · Journal of Cancer Research and Clinical Oncology
  57. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
    Paola Queirolo, Andrea Boutros, Enrica T. Tanda, Francesco Spagnolo, Pietro Quaglino · 2019 · Seminars in Cancer Biology
  58. Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
    Alan G. Ramsay · 2013 · British Journal of Haematology
  59. Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas
    Ashley Margol, Nathan John Robison, Janahan Gnanachandran, Long T. Hung, Rebekah J. Kennedy, Marzieh Vali, Girish Dhall, Jonathan L. Finlay, Anat Erdreich‐Epstein, Mark D. Krieger et al. · 2014 · Clinical Cancer Research
  60. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
    Andrew J.S. Furness, Frederick Arce Vargas, Karl S. Peggs, Sergio A. Quezada · 2014 · Trends in Immunology
  61. Opportunistic infections in patients treated with immunotherapy for cancer
    Chrisann Kyi, Matthew David Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow · 2014 · Journal for ImmunoTherapy of Cancer
  62. Can immunostimulatory agents enhance the abscopal effect of radiotherapy?
    Antonin Lévy, Cyrus Chargari, Aurélien Marabelle, Jean‐Luc Perfettini, Nicolas Magné, Éric Deutsch · 2016 · European Journal of Cancer
  63. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens
    Ren‐You Pan, Wen‐Hung Chung, Mu-Tzu Chu, Shu-Jen Chen, Hua-Chien Chen, Lei Zheng, Wen‐Hung Chung · 2018 · Journal of Immunology Research
  64. Renal effects of targeted anticancer therapies
    Camillo Porta, Laura Cosmai, Maurizio Alberto Gallieni, Paolo Pedrazzoli, Fabio Malberti · 2015 · Nature Reviews Nephrology
  65. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
    Jonathan M. Pitt, Marie Vétizou, Nadine Waldschmitt, Guido Kroemer, Mathias Chamaillard, Ivo Gomperts Boneca, Laurence Zitvogel · 2016 · Cancer Research
  66. Immune checkpoint blockade opens a new way to cancer immunotherapy
    Sanam Sadreddini, Behzad Baradaran, Ali Aghebati‐Maleki, Sevil Sadreddini, Dariush Shanehbandi, Ali Fotouhi, Leili Aghebati Maleki · 2018 · Journal of Cellular Physiology
  67. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
  68. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
    Shweta Joshi, Donald L. Durden · 2019 · Journal of Oncology
  69. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
    Robert D. Carlson, John C. Flickinger, Adam Eugene Snook · 2020 · Toxins
  70. Tumor mutational burden as a predictor of immunotherapy response in breast cancer
    Tess A. O’Meara, Sara M. Tolaney · 2021 · Oncotarget
  71. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation
    Andrea Pichler, Nadège Carrié, Marine Cuisinier, Samira Ghazali, Allison Voisin, Pierre‐Paul Axisa, Marie Tosolini, Céline Mazzotti, Dominic P. Golec, Sabrina Mahéo et al. · 2023 · Immunity
  72. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte–associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer
    Feifei Teng, Xiangjiao Meng, Li Kong, Dianbin Mu, Hui Zhu, Sujing Liu, Jianbo Zhang, Jinming Yu · 2015 · Translational research
  73. MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
    Agata Juszczak, Avinash Gupta, Niki Karavitaki, Mark Ross Middleton, Ashley Barry Grossman · 2012 · European Journal of Endocrinology
  74. Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
    Wenshi Wang, Daohai Yu, Amod A. Sarnaik, Bin Yu, MacLean S. Hall, Dawn Morelli, Yonghong Zhang, Xiuhua Zhao, Jeffrey S. Weber · 2012 · Journal of Translational Medicine
  75. The emerging role of immune checkpoint based approaches in AML and MDS
    Prajwal Chaitanya Boddu, Hagop M. Kantarjian, Guillermo Garcia‐Manero, James Patrick Allison, Padmanee Sharma, Naval Guastad Daver · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
  76. Correlation between sex and efficacy of immune checkpoint inhibitors ( PD ‐1 and CTLA ‐4 inhibitors)
    Yingcheng Charles Wu, Qianqian Ju, Keren Jia, Jingyan Yu, Hui Min Shi, Huiqun Wu, Maorong Jiang · 2018 · International Journal of Cancer
  77. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities
    R. Sinha, Kim Edmonds, Julia Newton‐Bishop, Martin Eric Gore, James Larkin, Louise A. Fearfield · 2012 · British Journal of Dermatology
  78. ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
    Francesco Torino, Agnese Barnabei, Rosa Maria Paragliola, Paolo Marchetti, Roberto Salvatori, Salvatore Maria Corsello · 2013 · European Journal of Endocrinology
  79. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
    Ching‐Yuan Chang, Haesuk Park, Daniel C. Malone, Ching-Yu Wang, Debbie L. Wilson, Yu‐Min Yeh, Sascha van Boemmel-Wegmann, Wei-Hsuan Lo-Ciganic · 2020 · JAMA Network Open
  80. Combinatorial therapy in tumor microenvironment: Where do we stand?
    Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  81. Immune checkpoint inhibitor-related hepatotoxicity: A review
    Devika Remash, David Stephen Prince, Catriona A. McKenzie, Simone Irene Strasser, Steven Kao, Ken Liu · 2021 · World Journal of Gastroenterology
  82. Therapeutic use of anti-CTLA-4 antibodies
    Christian U. Blank, Alexander Enk · 2014 · International Immunology
  83. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
    Matthew Weinstock, David F. McDermott · 2015 · Therapeutic Advances in Urology
  84. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Daphne Day, Aaron Richard Hansen · 2016 · BioDrugs
  85. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy
    Michael P. Vincent, Justin O. Navidzadeh, Sharan Kumar Reddy Bobbala, Evan Alexander Scott · 2022 · Cancer Cell
  86. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis
    Tsuyoshi Hamada, NaNa Keum, Reiko Nishihara, Shuji Ogino · 2016 · Journal of Gastroenterology
  87. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
    Roberto R. Rosato, Daniel Dávila‐González, Dong Soon Choi, Wei Ping Qian, Wen Chen, Anthony J. Kozielski, Helen H. Wong, Bhuvanesh Dave, Jenny C. Chang · 2018 · Breast Cancer Research
  88. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
    Yoshiyuki Nakamura, Ryota Tanaka, Hiroshi Maruyama, Yosuke Ishitsuka, Naoko Okiyama, Rei Watanabe, Manabu Fujimoto, Yasuhiro Fujisawa · 2018 · Japanese Journal of Clinical Oncology
  89. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
    Jeffrey S. Weber, Asim Amin, David R. Minor, Jonathan Siegel, David Berman, Steven J O'Day · 2011 · Melanoma Research
  90. Trial Watch
    Fernando Aranda, Erika Vacchelli, Alexander M.M. Eggermont, Jérôme Galon, Wolf H. Fridman, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2014 · OncoImmunology
  91. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer
    Sebastian Lundgren, Jonna Berntsson, Björn Nodin, Patrick Micke, Karin Jirström · 2016 · Journal of Ovarian Research
  92. Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
    Lawrence E. Flaherty, Megan K. D. Othus, Michael B. Atkins, Ralph J. Tuthill, John A. Thompson, John T. Vetto, Frank G. Haluska, Alberto S. Pappo, Jeffrey Alan Sosman, Bruce G. Redman et al. · 2014 · Journal of Clinical Oncology
  93. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
    Shi, Lewis Zhichang, Fu, Tihui, Guan, Baoxiang, Chen, Jianfeng, Blando, Jorge M., Allison, James P., Xiong, Liangwen, Subudhi, Sumit K., Gao, Jianjun, Sharma, Padmanee · 2016 · Nature Communications
  94. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
    Karim Tazi, Amanda Redden Hathaway, Codruta C. Chiuzan, Keisuke Shirai · 2014 · Cancer Medicine
  95. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
    Douglas Buckner Johnson, Vita Saranga‐Perry, Patrick Lavin, William Bryan Burnette, Stephen W. Clark, David Uskavitch, Deborah E. Wallace, Mark Andrew Dickson, Ragini Reiney Kudchadkar, Jeffrey Alan Sosman · 2014 · Journal of Clinical Oncology
  96. Strategies for modern biomarker and drug development in oncology
    Alan David Smith, Desam Roda, Timothy Anthony Yap · 2014 · Journal of Hematology & Oncology
  97. The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
    Andrea Botticelli, Concetta Elisa Onesti, Ilaria Grazia Zizzari, Bruna Cerbelli, Paolo Sciattella, Mario Alberto Occhipinti, Michela Roberto, Francesca Romana Di Pietro, Adriana Bonifacino, Michele Ghidini et al. · 2017 · Oncotarget
  98. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
    Kerry Lynn Reynolds, Molly Fisher Thomas, Michael Lawrence Dougan · 2018 · The Oncologist
  99. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
    Antonino Grassadonia, Isabella Sperduti, Patrizia Vici, Laura Iezzi, Davide Brocco, Teresa Gamucci, Laura Pizzuti, Marcello Maugeri‐Saccà, Paolo Marchetti, Gaetana Cognetti et al. · 2018 · Journal of Clinical Medicine
  100. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
    Jacques L. Cadranel, Anthony Canellas, Lise Matton, Marie Darrason, A. Parrot, Jean‐Marc Naccache, A. Lavolé, Anne-Marie Ruppert, Vincent Fallet · 2019 · European Respiratory Review